ArticleBMC microbiology2022
Effects of different cultivation conditions on the production of β-cyclocitral and β-ionone in Microcystis aeruginosa.
Article in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Effect of Light Intensity on the Production of Volatile Organic Compounds by Submerged MacrophyteEcology and evolution · 2026Article
- Pharmacognostic Characterization, Phytochemical Profiling, and In Vitro Biological Evaluation ofInternational journal of molecular sciences · 2026Article
- Wild grown Portulaca oleracea as a novel magnetite based carrier with in vitro antioxidant and cytotoxicity potential.Scientific reports · 2025Article
- Phytochemical and Pharmacological Insights intoMolecules (Basel, Switzerland) · 2025Review
- β-Cyclocitral: Emerging Bioactive Compound in Plants.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyanobacteria blooms have become a major environmental problem and concern because of secondary metabolites produced by cyanobacteria released into the water. Cyanobacteria produce volatile organic compounds (VOCs), such as the compounds β-cyclocitral and β-ionone, which comprise odors, off-flavors, defense compounds, as well as growth regulators. Therefore, the general objective of this work was to evaluate the VOCs produced by two strains of Microcystis aeruginosa, differing in their ability to produce microcystins (LTPNA 01-non-producing and LTPNA 08-toxin-producing). The analysis of VOC production was carried out in (1) normal culture conditions, (2) under different light intensities (LI), and (3) after the external application of β-ionone in both cultures.
resultsThe results showed that β-cyclocitral and β-ionone are produced in all growth phases of LTPNA 01 and LTPNA 08. Both strains were producers of β-cyclocitral and β-ionone in normal culture conditions. It was observed that the β-cyclocitral concentration was higher than β-ionone in all light intensities investigated in this study. Additionally, the strain LTPNA 01 produced more β-cyclocitral than LTPNA 08 at almost all times and LIs analyzed. However, the strain LTPNA 08 produced more β-ionone, mainly at the initial times. In addition, the experiment results with the external addition of β-ionone in the cultures showed that the strain LTPNA 01 produced more β-cyclocitral in control conditions than in treatment. Nonetheless, β-ionone production was higher in treatment conditions in LTPNA 08, indicating that the addition of β-ionone may favor the production of these compounds and inhibit the production of β-cyclocitral.
conclusionOur results showed that some abiotic factors, such as different light intensities and external application of β-ionone, can be triggers that lead to the production of VOCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.